The Modeling and Trial Simulation Software
With The Most Comprehensive Disease Model Library
A complete solution for trial simulation
& protocol design optimization
Increase the chances of success for your clinical trial
Get a headstart with a disease models library
Access disease models from nova's expert modeling team, across a wide range of therapeutic areas.
Run a complete trial in 5 minutes
Test unlimited protocol designs on an endless number of virtual patients. Run complex trials in a few seconds.
Optimize your trial design
Find responder biomarkers, compare eligibility criteria, run advanced analysis and overlay results with your own data.
A wide range of disease models from experts
NSCLC
Nova's non small cell lung cancer (NSCLC) disease model of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LUAD)
Atopic Dermatitis
Nova’s atopic dermatitis (AD) model accounts for the interplay between the skin barrier and the immune system. It describes the key pathways and biomarkers influencing disease course, including the mechanisms...
Asthma
Nova’s Asthma model describes the immune response following a provocation by an allergen and leading to airway inflammation and subsequent decrease of lung functions. The inter-species nature of the model was calibrated to reproduce the dynamics of 11 key immune variables...
Our success stories
Mathias Bergeron
Medical Director Oncology
Janssen France
We’ve collaborated with Novadiscovery on the development of the NSCLC mechanistic model for over three years, and we’re thrilled to see the simulation results validated on one of our studies. This predictive model can now be employed to simulate hypotheses that we cannot test in real life, especially in populations with rare driver mutations like the exon20 insertion on EGFR.
Accurately predict the results of Janssen's Phase III MARIPOSA trial using only publicly available documentation in collaboration with Prof. Michaël Duruisseaux.
Phase III
Disease model
NSCLC - EGFR
Treatment model
Osimertinib
Amivantamab
This model predicts findings from a three-year, global Phase III trial using the jinkō platform. The in silico trial simulation has demonstrated the potential to significantly reduce the time and cost burden associated with traditional clinical trials.
Our success stories
Prof. Michaël Duruisseaux
Researcher and thoracic oncologist
Hospices Civils de Lyon, Cancer Research Center of Lyon, France
This work simulating this phase III trial revealed the potential of in silico clinical trials to define a new future for drug development. Results like these, if leveraged before human trials begin, will enable the recruitment of the most relevant patient population, optimize trial design, and ultimately accelerate all therapeutic development in our shared hope that cancer becomes an eminently curable disease. I strongly believe that in silico clinical trials can help in the very near future to set a ‘target’ Hazard Ratio that will be used to build the statistical hypothesis of the next-generation of clinical trials.
Accurately predict the results of AstraZeneca's Phase III FLAURA2 trial using only publicly available documentation in collaboration with Prof. Michaël Duruisseaux.
Phase III
Disease model
NSCLC - EGFR
Treatment models
Osimertinib
Cisplatin
Pemetrexed
This model prospectively predicted findings from a three-year, global Phase III trial using the jinkō platform. This in silico trial simulation has demonstrated the potential to significantly reduce the time and cost burden associated with traditional clinical trials.
Our success stories
Thierry Marquet
General Manager, Takeda France
We are applying jinko’s virtual population simulation technology and in silico research approach as a complement to clinical development plans to support health technology assessment for our innovative therapies.
Apply for a new marketing authorization and present new results to demonstrate the higher efficacy of Natpar compared to the standard of care.
Market access
Disease model: hypoparathyroidism
Treatment model: Natpar
Reduce payer uncertainty to speed up acceptance and allow rare disease patients to access Natpar earlier.
Previous
Next
A best-in class trial simulation platform
All of nova’s unique in-silico modeling expertise in one user-friendly software
Modeling & Simulation
Results analytics
Knowledge & Data Management
Modeling & Simulation
-> Build your model or edit one from our library with powerful capabilities, simulate a trial’s outcomes in just a few minutes, test unlimited protocol designs on an endless number of virtual patients, iterate, re-sample and optimise your trial design.
Results analytics
-> Display simulation results (protocol comparisons, timeseries, aggregated metrics, scatter plots…), visualize population subgroups, explore patient baseline impact on any quantity of interest using tornado plots and perform survival analysis.
Knowledge & Data Management
-> Consolidate all necessary references and data in one central secured location and curate relevant scientific information with your team. Easily integrate this data with your documentation and models for full simulations traceability.
Request a demo
Want to run your first in silico clinical trial
in under 5 min?
Get a demo from our experts!
Join our Newsletter
Join our newsletter to receive updates about the latest features in Jinkō.